Clinical Scorecard: Long-Term Analysis of Plasma Metabolite Changes During Menopause and Their Links to Subsequent Development of Metabolic Syndrome
At a Glance
Category
Detail
Condition
Metabolic Syndrome (MetS) development during and after menopause
Key Mechanisms
Longitudinal changes in plasma metabolites, especially branched-chain amino acids (BCAAs), homocysteine metabolism, and glutamate levels
Target Population
Premenopausal and menopausal women aged 35-74 years
Care Setting
Community-based cohort study with longitudinal follow-up
Key Highlights
Menopause is associated with significant changes in 18 plasma metabolites, notably those involved in BCAA metabolism, urea cycle, and homocysteine metabolism.
Elevated glutamate levels during menopause are linked to nearly doubled risk of developing MetS.
Higher glutamate, valine, leucine, and cystine levels correlate with increased risk of hyperglycemia, a key MetS component.
Guideline-Based Recommendations
Diagnosis
Assess menopausal status and monitor plasma metabolites, including BCAAs and homocysteine-related metabolites, for early detection of metabolic alterations.
Use capillary electrophoresis mass spectrometry for detailed metabolomic profiling when available.
Management
Target metabolic alterations during menopause to prevent or delay MetS development, focusing on modifiable risk factors such as hyperglycemia and dyslipidemia.
Consider lifestyle interventions addressing diet and physical activity to modulate amino acid metabolism.
Monitoring & Follow-up
Longitudinal monitoring of plasma metabolites, especially glutamate and BCAAs, to identify women at higher risk for MetS.
Regular screening for MetS components (hyperglycemia, dyslipidemia, hypertension, abdominal obesity) in postmenopausal women.
Risks
Increased risk of cardiovascular disease and stroke associated with MetS components post-menopause.
Elevated homocysteine and altered amino acid metabolism contribute independently to metabolic and vascular risks.
Patient & Prescribing Data
Premenopausal and menopausal women without baseline MetS
Monitoring metabolite changes such as glutamate and BCAAs may guide early interventions to reduce MetS risk; however, specific pharmacologic treatments targeting these metabolites were not detailed.
Clinical Best Practices
Incorporate metabolomic profiling in research and potentially clinical settings to better understand metabolic changes during menopause.
Focus on early identification of metabolic alterations to implement preventive strategies against MetS.
Educate patients about increased metabolic risks during menopause and the importance of lifestyle modifications.
A large Epic Cosmos analysis linked vaginal estrogen prescribing with lower rates of sepsis, hospital admission, and death following recurrent urinary tract infection, but researchers cautioned that prescribing may also mark broader differences in care.
